All In Biotech

Drug Trial Radar · NCT01067820

ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Last checked: Nov 19, 2026Latest source record: Jun 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

324

Actual

Start

Sep 2011

Primary completion

May 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Resverlogix CorpIndustry
Sponsor type
Industry
Collaborators
The Cleveland Clinic
First posted
Feb 12, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to characterize the early effects of ApoA-I synthesis with RVX000222 on coronary atherosclerotic disease when administered to patients with coronary artery disease and have a low HDL-C level, as assessed by Intravascular Ultrasound (IVUS) in addition to standard background therapy.

Conditions

  • Coronary Artery Disease

Interventions

  • RVX000222Drug

    capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks

  • Placebo RVX000222Drug

    capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The nominal change in percent atheroma volume (PAV) from baseline to 26 weeks postrandomization, as determined by intravascular ultrasound (IVUS) within the RVX000222 treated group.Time frame: baseline to 26 weeks postrandomization

Locations

58 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Corrientes, Argentina

  • Site not named

    San Isidro, Argentina

  • Site not named

    La Plata, Buenos Aires, Argentina

  • Site not named

    Brussels, Belgium

  • Site not named

    Charleroi, Belgium

  • Site not named

    Edegem, Belgium

  • Site not named

    Genk, Belgium

  • Site not named

    Brasília, Brazil

  • Site not named

    Cariacica, Brazil

  • Site not named

    Curitiba, Brazil

  • Site not named

    Goiânia, Brazil

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Uberlândia, Brazil

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Pécs, Hungary

  • Site not named

    Szeged, Hungary

  • Site not named

    Alkmaar, Netherlands

  • Site not named

    Amsterdam, Netherlands

  • Site not named

    Eindhoven, Netherlands

  • Site not named

    Enschede, Netherlands

  • Site not named

    Nijmegen, Netherlands

  • Site not named

    Rotterdam, Netherlands

  • Site not named

    Zwolle, Netherlands

  • Site not named

    Katowice, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.